This would be consistent with the demonstrated NOT-elicited inhibition of JAK2 activation, and the documented roles of JAK2/STAT3 signaling in oncogenicity, maintenance of cancer stemness, cellular survival under stress, and resistance to multiple anticancer therapies [8,9,10,11,24,25,26,27,28,29]. This evidence concerns the gene JAK2 and cancer.